Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic's Melody Transcatheter Pulmonary Valve Gets FDA Panel Date

This article was originally published in The Gray Sheet

Executive Summary

FDA's Circulatory System Devices Panel will review a humanitarian device exemption application for Medtronic's Melody transcatheter pulmonary valve and Ensemble delivery system July 22, according to a July 2 Federal Register notice

You may also be interested in...



Medtronic Catapults Into Transcatheter Valve Market With Billion-Dollar Buys

Medtronic will enter the high-growth, minimally invasive aortic heart valve market through two acquisitions worth more than $1 billion

Medtronic Melody Data Sings; Transcatheter Heart Valve Awaits HDE

Feasibility trial results show Medtronic's Melody transcatheter pulmonary heart valve reduces right ventricular volume by 18% in patients with dysfunctional right ventricular outflow tract conduits

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Topics

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel